Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - desvenlafaxine, quantity: 100 mg - tablet, modified release - excipient ingredients: alginic acid; magnesium stearate; povidone; purified talc; hypromellose; citric acid monohydrate; microcrystalline cellulose; titanium dioxide; macrogol 8000; iron oxide red; iron oxide black - for the treatment of major depressive disorder, including the preventiton of relapse. not indicated for paediatric use.

United States - English - NLM (National Library of Medicine)

macoven pharmaceuticals - desvenlafaxine (unii: ng99554anw) (desvenlafaxine - unii:ng99554anw) - desvenlafaxine 50 mg - desvenlafaxine extended-release tablets are indicated for the treatment of adults with major depressive disorder (mdd) [see clinical studies (14)] . - hypersensitivity to desvenlafaxine succinate, venlafaxine hydrochloride or to any excipients in the desvenlafaxine extended-release tablets formulation.  angioedema has been reported in patients treated with desvenlafaxine [see adverse reactions (6.1)] . - the use of maois intended to treat psychiatric disorders with desvenlafaxine extended-release tablets or within 7 days of stopping treatment with desvenlafaxine extended-release tablets is contraindicated because of an increased risk of serotonin syndrome. the use of desvenlafaxine extended-release tablets within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration  (2.8)   and  warnings and precautions  (5.2)]. -   starting desvenlafaxine extended-release tablets in a patient who is being treated with maois such as linezolid or intraveno

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - desvenlafaxine benzoate, quantity: 146.32 mg (equivalent: desvenlafaxine, qty 100 mg) - tablet, modified release - excipient ingredients: hypromellose; colloidal anhydrous silica; purified talc; microcrystalline cellulose; stearic acid; titanium dioxide; sunset yellow fcf aluminium lake; iron oxide red; polyvinyl alcohol; macrogol 3350 - desvenlafaxine is indicated for the treatment of major depressive disorder, including the prevention of relapse.,desvenlafaxine is not indicated for paediatric use.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - desvenlafaxine benzoate, quantity: 73.16 mg (equivalent: desvenlafaxine, qty 50 mg) - tablet, modified release - excipient ingredients: hypromellose; colloidal anhydrous silica; purified talc; microcrystalline cellulose; stearic acid; titanium dioxide; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - desvenlafaxine is indicated for the treatment of major depressive disorder, including the prevention of relapse.,desvenlafaxine is not indicated for paediatric use.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - desvenlafaxine, quantity: 50 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; hypromellose; citric acid monohydrate; magnesium stearate; povidone; purified talc; alginic acid; titanium dioxide; macrogol 6000; iron oxide red - for the treatment of major depressive disorder, including the preventiton of relapse. not indicated for paediatric use.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - desvenlafaxine benzoate, quantity: 146.32 mg (equivalent: desvenlafaxine, qty 100 mg) - tablet, modified release - excipient ingredients: hypromellose; colloidal anhydrous silica; purified talc; microcrystalline cellulose; stearic acid; titanium dioxide; sunset yellow fcf aluminium lake; iron oxide red; polyvinyl alcohol; macrogol 3350 - desvenlafaxine is indicated for the treatment of major depressive disorder, including the prevention of relapse.,desvenlafaxine is not indicated for paediatric use.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - desvenlafaxine benzoate, quantity: 73.16 mg (equivalent: desvenlafaxine, qty 50 mg) - tablet, modified release - excipient ingredients: hypromellose; colloidal anhydrous silica; purified talc; microcrystalline cellulose; stearic acid; titanium dioxide; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - desvenlafaxine is indicated for the treatment of major depressive disorder, including the prevention of relapse.,desvenlafaxine is not indicated for paediatric use.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - desvenlafaxine, quantity: 100 mg - tablet, modified release - excipient ingredients: magnesium stearate; purified talc; povidone; hypromellose; citric acid monohydrate; microcrystalline cellulose; alginic acid; titanium dioxide; macrogol 8000; iron oxide red; iron oxide black - for the treatment of major depressive disorder, including the preventiton of relapse. not indicated for paediatric use.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - desvenlafaxine, quantity: 100 mg - tablet, modified release - excipient ingredients: purified talc; microcrystalline cellulose; alginic acid; magnesium stearate; hypromellose; povidone; citric acid monohydrate; titanium dioxide; macrogol 8000; iron oxide red; iron oxide black - for the treatment of major depressive disorder, including the preventiton of relapse. not indicated for paediatric use.

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - desvenlafaxine (unii: ng99554anw) (desvenlafaxine - unii:ng99554anw) - desvenlafaxine 50 mg - desvenlafaxine is indicated for the treatment of adults with major depressive disorder (mdd) [see clinical studies (14)] . - hypersensitivity to desvenlafaxine succinate, venlafaxine hydrochloride or to any excipients in the desvenlafaxine extended-release tablets formulation.  angioedema has been reported in patients treated with desvenlafaxine [see adverse reactions (6.1)] . - the use of maois intended to treat psychiatric disorders with desvenlafaxine or within 7 days of stopping treatment with desvenlafaxine is contraindicated because of an increased risk of serotonin syndrome. the use of desvenlafaxine within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration (2.7) and warnings and precautions (5.2)]. - starting desvenlafaxine in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see dosage and administration (2.8) and